What is VIVS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for VIVS?

P/E (TTM) is n/a and 52-week range is $0.19 to $3.54 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s VIVS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for VIVS?

The company profile lists revenue (TTM) near $258K, net income (TTM) near $-2.84B, EPS (TTM) near $-4.45 when available from the market-data feed. Figures are informational and may lag live markets.

Where is VivoSim Labs Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 12.1M shares outstanding, ISIN US68620A3023 when available from company profile and filing metadata.

VivoSim Labs Inc

$VIVS

Health Care · Biotechnology

IR Run Scenarios

$0.18

+1.64%

VivoSim Labs Inc

$VIVS

Health Care · Biotechnology

IR Run Scenarios

$0.18

+1.64%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

VivoSim Labs, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. The company is headquartered in San Diego, California and currently employs 13 full-time employees. The company went IPO on 2013-08-02. The firm offers partners liver and intestinal toxicology insights using its new approach methodologies (NAM) models. The firm offers liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development. The company uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. The firm also advances product candidates to treat inflammatory bowel disease (IBD) discovered and developed using its complex human tissue intestinal models.

Employees

13

Website

organovo.com/

IPO

2013-08-02

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (TTM)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US68620A3023

Headquarters

San Diego, California, US

Shares outstanding

12.1M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

11.09%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

VivoSim Labs, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. The company is headquartered in San Diego, California and currently employs 13 full-time employees. The company went IPO on 2013-08-02. The firm offers partners liver and intestinal toxicology insights using its new approach methodologies (NAM) models. The firm offers liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development. The company uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. The firm also advances product candidates to treat inflammatory bowel disease (IBD) discovered and developed using its complex human tissue intestinal models.

Employees

13

Website

organovo.com/

IPO

2013-08-02

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)